Aqueous versus non-aqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (mk-2) inhibitor in rats

Journal of Pharmaceutical Sciences

Volumn 98, Issue 1, 2009, Pages 248-256

  Chiang, Po Chang ^a   South, Sarah A ^a   Daniels, J Scott ^a   Anderson, David R ^a   Wene, Steve P ^a   Albin, Lesley A ^a   Mourey, Robert J ^a   Selbo, Jon G ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bioavailability; In vivo; Inhibitor; MK2; Non aqueous; Oral; Salt

Indexed keywords

DRUG VEHICLE; MESYLIC ACID; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PYRIDINE; RAS PROTEIN;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WATER CONTENT;

EID: 58149242453     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21425     Document Type: Article

References (21)

1. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M. 2006. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 26:2399-2407.
2. Dean JL, Sully G, Clark AR, Saklatvala J. 2004. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 16: 1113-1121.
3. Fechir M, Linker K, Pautz A, Hubrich T, Forster-mann U, Rodriguez-Pascual F, Kleinert H. 2005. Tristetraprolin regulates the expression of the human inducible nitric-oxide synthase gene. Mol Pharmacol 67:2148-2161.
4. Tietz AB, Malo A, Diebold J, Kotlyarov A, Herbst A, Kolligs FT, Brandt-Nedelev B, Halangk W, Gaestel M, Göke B, Sehäfer C. 2006. Gene deletion of MK2 inhibits TNF-α and IL-6 and protects against cerulein-induced pancreatitis. Am J Physiol Gastrointest Liver Physiol 290:G1298-G1306.
5. Young DA, Hegen M, Ma HLM, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith KC Jr, Collins M. 2007. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56:1152-1163.
6. Almholt DLC, Loechel F, Nielsen SJ, Krog-Jensen K, Terry R, Bjørn SP, Pedersen HC, Præstegaard M, Møller S, Heide M, Pagliaro L, Mason AJ, Butcher S, Dahl SW. 2004. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 Redistribution® screen. Assay Drug Dev Tech 2:7-20.
7. Zhang T, Kruys V, Huez G, Gueydan C. 2002. AU-rich element-mediated translational control: Complexity and multiple activities of trans-activating factors. Biochem Soc Trans 30:952-958.
8. Wilson GM, Sutphen K, Moutafis M, Sinha S, Brewer G. 2001. Session 12: Post-transcriptional regulation of cytokine expression. Immunology 104:45-46.
9. Comite GD, Marinosci A, Dimatteo P, Manfredi A, Rovere-querini A, Ldissera E, Aiello P, Corti A, Sabbadini MA. 2006. Neuroendocrine modulation induced by selective blockade of TNF-α in rheumatoid arthritis. Ann NY Acad Sci (Basic and Clinical Aspects of Neuroendocrine Immunology and Rheumatic Diseases), 1069:428-437.
10. Thong BYH, Vasoo S, Koh ET. 2006. The use of anti-tumour necrosis factor-α therapies for rheumatoid arthritis in Singapore. APLAR J Rheumatol 9:157-160.
11. Stahl PH, Wermuth GG. 2002. Handbook of Pharmaceutical Salts Property, Selection, and Use. Weinheirn, Germany: Wiley-VCH.
12. Berge SM, Bighley LD, Monkhouse DC. 1977. Pharmaceutical salts. J Pharm Sci 74:815-820.
13. Morris KR, Fakes MG, Thakur AB, Newman AW, Serajuddin ATM. 1994. Integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 105:209-217.
14. Li S, Wong S, Sethia S, Joshi HAYM, Serajuddin ATM. 2005. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res 22:628- 635.
15. Parshad H, Frydenvang K, Liljefors T, Cornett C, Larsen C. 2003. Assessment of drug salt release from solutions, suspensions and in situ suspensions using a rotating dialysis cell. Eur J Pharm Sci 19: 263-272.
16. Jones HP, Davey RJ, Cox BG. 2005. Crystallization of a salt of a weak organic acid and base: Solubility relations, supersaturation control and polymorphic behavior. J Phys Chem B 109:5273-5278.
17. Spanos N, Koutsoukos PG. 1998. Kinetics of precipitation of calcium carbonate in alkaline pH at constant supersaturation. Spontaneous and seeded growth. J Phys Chem B 102:6679-6684.
18. Kwon Y. 2001. Handbook of Essential Pharmacokinetics, Pharmacodynamics, and Drug Metabolism for Industrial Scientists. New York, NY, USA: Kluwer Academic/Plenum Publishers.
19. Rowe R, Sheskeym PJ, Weller PJ. Handbook of Pharmaceutical Excipients, 4th edition. London, UK: Pharmaceutical Press.
20. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15:11-22.
21. Dressman JB, Reppas C. 2000. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci ll:S73-S80.